Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-04-18

Clinical Trial Update: mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a sequence of mFOLFIRINOX followed by hepatic arterial infusion of floxuridine with dexamethasone and systemic mFOLFIRI for unresectabl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEXAMETHASONE (Dexamethasone)
  • Floxuridine (floxuridine)
  • mFOLFIRI
  • mFOLFIRINOX

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING